Adverse Effects of Clopidogrel: a Cross Sectional Study of the FDA Adverse Event Reporting System Database

被引:0
|
作者
Al-Saikhan, Fahad [1 ]
Ahmad, Nehad [1 ]
Abd-Elaziz, Mohamed [2 ]
Iqbal, Muhammad Shahid [1 ]
机构
[1] Prince Sattam Bin Abdulaziz Univ, Pharm Coll, Dept Clin Pharm, Al Kharj, Saudi Arabia
[2] Mansoura Univ, Mansoura Fac Med, Dept Clin Pharmacol, Mansoura, Egypt
来源
LATIN AMERICAN JOURNAL OF PHARMACY | 2022年 / 41卷 / 07期
关键词
adverse event reporting; clopidogrel; FAERS; post-marketing; DRUG-INTERACTIONS; HEPATOTOXICITY;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Unexpected effects could also occur after the marketing of clopidogrel. So, it is necessary to ensure clopidogrel continued safety once it reaches the general population. The present study aimed to describe the adverse effects reports of clopidogrel during the previous years. It included a descriptive analysis of all reported AEs associated with clopidogrel using the FDA Adverse Event Reporting System. From 1998 to the end of 2021, a total of 21566 reports of clopidogrel adverse events were submitted to FAERS. Most of the reports were submitted by healthcare professionals (88.43%). The most reported clopidogrel adverse reactions were anemia (7.88%), drug interactions (7.48%), gastrointestinal hemorrhage (6.27%), and dyspnea (5.06%). Nowadays, clopidogrel is widely used in clinical practice, so the occurrence of different side effects particularly the hematological side effects should be considered by healthcare providers. Moreover, the pharmacists should check for the interactions between clopidogrel and other medications before dispensing clopidogrel.
引用
收藏
页码:1388 / 1391
页数:4
相关论文
共 50 条
  • [21] Serious Adverse Drug Events Reported to the FDA: Analysis of the FDA Adverse Event Reporting System 2006-2014 Database
    Sonawane, Kalyani B.
    Cheng, Ning
    Hansen, Richard A.
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2018, 24 (07): : 682 - 690
  • [22] Adverse event profile of CGRP monoclonal antibodies: findings from the FDA adverse event reporting database
    Wang, Qi
    Liu, Jingfang
    Sun, Hao
    Dong, Yongfei
    Tan, Weiliang
    Tang, Zaixiang
    Jiang, Yiguo
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (01) : 107 - 117
  • [23] Post-marketing pharmacovigilance study of inclisiran: mining and analyzing adverse event data from the FDA Adverse Event Reporting System database
    Zou, Dan
    Hu, Qiaozhi
    Liu, Ying
    Yu, Lei
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2024,
  • [24] Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
    Iarikov D.
    Wassel R.
    Farley J.
    Nambiar S.
    [J]. Infectious Diseases and Therapy, 2015, 4 (4) : 433 - 458
  • [25] Assessing Adverse Drug Reactions Reported for New Respiratory Medications in the FDA Adverse Event Reporting System Database
    Kim, Hyunwoo
    Pfeiffer, Colin M.
    Gray, Matthew P.
    Stottlemyer, Britney A.
    Boyce, Richard D.
    Kane-Gill, Sandra L.
    [J]. RESPIRATORY CARE, 2021, 66 (11) : 1739 - 1745
  • [26] Ocular adverse events of cenegermin used in neurotrophic keratopathy: an analysis of the FDA adverse event reporting system database
    Li, Yunfei
    Yang, Haiyun
    Gao, Yuan
    He, Weimin
    [J]. EXPERT OPINION ON DRUG SAFETY, 2024, 23 (03) : 385 - 391
  • [27] Atezolizumab and severe cutaneous adverse reactions: Data mining of the FDA Adverse Event Reporting System (FAERS) database
    Pecere, A.
    Bisinella, G. C.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1251 - S1251
  • [28] Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database
    Liu, Ruixue
    Liu, Chunxiao
    Feng, Dianwei
    Guo, Tongxin
    Wang, Ying
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [29] Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database
    Rashid Kazerooni
    Edward P. Armstrong
    [J]. Clinical Drug Investigation, 2018, 38 : 867 - 872
  • [30] Botulinum Toxin Type A Overdoses: Analysis of the FDA Adverse Event Reporting System Database
    Kazerooni, Rashid
    Armstrong, Edward P.
    [J]. CLINICAL DRUG INVESTIGATION, 2018, 38 (09) : 867 - 872